Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2018

View Archived Issues

New method to up fetal hemoglobin

A new take on targeting Wnt

Red blood cell hitchhiking improves nanocarrier drug delivery to specific target organs

Tau protein can be targeted by small drug-like molecules to avoid aggregation

In vivo studies show potential of CSTI-300 for irritable bowel syndrome-diarrhea

Phase 0 results presented for tau-imaging tracer [18F]JNJ-067

Evaluation of [11C]BU-99008 as a marker for AD pathology mechanisms

Kinase inhibitor targets leishmaniasis

First patient dosed in phase I study of TP-0184 for the treatment of advanced solid tumors

Positive topline data presented from pivotal study of dasotraline in binge eating disorder

Researchers unveil mechanism of action of the antiplatelet compound LASSBio-788

BeiGene initiates Chinese phase III trial of first-line tislelizumab therapy for advanced NSCLC

Researchers prove NE-driven feeding-suppression circuit in mice

Mitobridge describes new ACMSD inhibitors

Intra-Cellular Therapies identifies mu-opioid receptor antagonists

New phosphodiesterase PDE2A inhibitors presented by Dart NeuroScience

Shanghai Fochon Pharmaceutical Co., Fochon Pharma patent Bcl-2 inhibitors

Henan Metab Biopharma divulges Mcl-1 inhibitors

ALTA-1L phase III study of brigatinib meets primary endpoint

Bioasis announces positive results from microdialysis mouse study of xB3-001

Corbus plans phase III trial of lenabasum in dermatomyositis

Destiny Pharma reports encouraging phase I safety data for XF-73

Phase I study data support biosimilarity criteria of GBR-310 to reference omalizumab

Phase Ib safety data for OPT-302 in DME support progression to phase IIa

FDA places clinical hold on phase I/IIa DMD trial due to out-of-specification production lot

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Pharma industry faces long haul to get return on investment from AI
BioWorld Science
Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on...